HER2-Directed Therapies in NSCLC: Navigating Clinical Insights, Integration Challenges, and Access Considerations : Episode 14
Opinion
Video
Patient Selection and Personalized Treatment Strategies
Key Takeaways
- Transitioning from IV to oral medications requires careful management of adherence, side effects, and therapeutic efficacy to ensure optimal patient outcomes.
- Patient-specific factors, such as comorbidities and drug interactions, are critical in optimizing treatment during the transition from IV to oral medications.
An overview of challenges in transitioning from IV to oral medications and guidance on identifying NSCLC patient populations most likely to benefit from HER2-directed therapies through informed patient selection strategies.
Video content above is prompted by the following:
- What challenges may exist when transitioning from IV to oral medications?
- Which NSCLC patient populations are most likely to benefit from HER2-directed therapies and how should clinicians approach patient selection?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
